Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling

Journal of Medical Investigation

Volumn 53, Issue 1-2, 2006, Pages 9-19

  Takahashi, Masayuki ^c   Teh, Bin T ^a   Kanayama, Hiro Omi ^b  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NONE

Author keywords

Gene expression profiling; Prognosis; Renal cell carcinoma

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE INHIBITOR; IMATINIB;

CANCER SURVIVAL; CHRONIC LEUKEMIA; CLEAR CELL CARCINOMA; DNA FINGERPRINTING; DNA MICROARRAY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MICROARRAY ANALYSIS; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PROGNOSIS; REVIEW; UNINDEXED SEQUENCE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33645807880     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.53.9     Document Type: Review

References (44)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr: Rising incidence of renal cell cancer in the United States. Jama 281: 1628-1631, 1999
3. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B: Obesity, hypertension, the risk of kidney cancer in men. N Engl J Med 343: 1305-1311, 2000
4. Moyad MA: Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol 19: 280-293, 2001
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2002
6. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23: 832-841, 2005
7. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL: Multiplexed biochemical assays with biological chips. Nature 364: 555-556, 1993
8. Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, Sone S, Nakamura Y: Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 13: 3029-3043, 2004
9. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang N J, Furge KA, Kanayama H, Kagawa S, Teh BT: Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22: 6810-6818, 2003
10. Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, Kagawa S, Hoekstra P, Curry J, Yang XJ, Teh BT: Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 64: 4117-4121, 2004
11. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20: 2376-2381, 2002
12. Takahashi M, Papavero V, Yuhas J, Kort E, Kanayama HO, Kagawa S, Baxter RC, Yang XJ, Gray SG, Teh BT: Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol 26: 923-931, 2005
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001
14. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM: alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287: 1662-1670, 2002
15. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo, AM: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002
16. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M: Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 11: 6558-6566, 2005
17. Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M, Vogelzang NJ, Lin F, Krausz T, Teh BT, Yang XJ: Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 28: 69-76, 2004
18. Takahashi M, Yang XJ, McWhinney S, Sano N, Eng C, Kagawa S, Teh BT, Kanayama HO: cDNA microarray analysis assists in diagnosis of malignant intrarenal pheochromocytoma originally masquerading as a renal cell carcinoma. J Med Genet 42: e 48, 2005
19. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999
20. Saito K, Saito T, Draganac PS, Andrews RB, Lange RD, Etkin LD, Farkas WR: Secretion of ceruloplasmin by a human clear cell carcinoma maintained in nude mice. Biochem Med 33: 45-52, 1985
21. Pejovic M, Djordjevic V, Ignjatovic I, Stamenic T, Stefanovic V: Serum levels of some acute phase proteins in kidney and urinary tract urothelial cancers. Int Urol Nephrol 29: 427-432, 1997
22. Kirschmann DA Seftor EA, Nieva DR, Mariano EA, Hendrix MJ: Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res Treat 55: 127-136, 1999
23. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR: Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. Faseb J 14: 2589-2600, 2000
24. Janssen AM, van Duijn W, Oostendorp-Van De Ruit MM, Kruidenier L, Bosman CB, Griffioen G, Lamers CB, van Krieken JH, van De Velde CJ, Verspaget HW: Metallothionein in human gastrointestinal cancer [In Process Citation]. J Pathol 192: 293-300, 2000
25. Nguyen A, Jing Z, Mahoney PS, Davis R, Sikka SC, Agrawal KC, Abdel-Mageed AB: In vivo gene expression profile analysis of metallothionein in renal cell carcinoma [In Process Citation]. Cancer Lett 160: 133-140, 2000
26. Izawa JI, Moussa M, Cherian MG, Doig G, Chin JL: Metallothionein expression in renal cancer. Urology 52: 767-772, 1998
27. Zhu YY, Takashi M, Miyake K, Kato K: An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J Urol 146: 469-472, 1991
28. Xiang YY, Ladeda V, Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 20: 7408-7412, 2001
29. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lockwood GA, Rosenblum ND, Filmus J: Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson - Golabi - Behmel syndrome. J Cell Biol 146: 255-264, 1999
30. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98: 9754-9759, 2001
31. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998
32. Rhodes DR, Miller JC, Haab BB, Furge KA CIT: identification of differentially expressed clusters of genes from microarray data. Bioinformatics 18: 205-206, 2002
33. Engel JD, Kundu SD, Yang T, Lang S, Goodwin S, Janulis L, Cho JS, Chang J, Kim SJ, Lee C: Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology 54: 164-170, 1999
34. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798-802, 1999
35. Ahonen M, Baker AH, Kahari VM: Adenovirus -mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58: 2310-2315, 1998
36. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994
37. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Iinehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994
38. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994
39. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schulte DS: Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 21: 621-635, 1997
40. Delahunt B, Eble JN: Papillary renal cell carcinomas clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10: 537-544, 1997
41. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Soderhall S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh BT: Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 62: 6598-6605, 2002
42. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22: 847-852, 2003
43. Demetri GD: Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI 571). Eur J Cancer 38 (Suppl 5): S52-59, 2002
44. Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT: Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 100: 976-985, 2004